- Home
- MDRR vs CUE Comparison
MDRR vs CUE Comparison
Compare MDRR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDRR | CUE |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 17.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | MDRR | CUE |
|---|---|---|
| Price | $11.41 | $30.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 1.2K | ★ 22.2M |
| Earning Date | 03-02-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $9.55 | $0.17 |
| 52 Week High | $14.52 | $38.00 |
Technical Indicators
Market Signals| Indicator | MDRR | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 85.87 |
| Support Level | $11.00 | $0.40 |
| Resistance Level | $12.45 | N/A |
| Average True Range (ATR) | 0.08 | 3.81 |
| MACD | 0.01 | 2.86 |
| Stochastic Oscillator | 37.28 | 80.56 |
Price Performance
Historical ComparisonAbout MDRR Medalist Diversified REIT Inc.
Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.